Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12620000416998
Ethics application status
Approved
Date submitted
12/03/2020
Date registered
27/03/2020
Date last updated
12/10/2022
Date data sharing statement initially provided
27/03/2020
Type of registration
Prospectively registered

Titles & IDs
Public title
Improving muscle strength in young people with Prader-Willi syndrome: a phase II randomised trial
Scientific title
The effect of exercise on muscle strength in young people with Prader-Willi syndrome: a phase II randomised trial
Secondary ID [1] 298081 0
None
Universal Trial Number (UTN)
Trial acronym
PRESTO
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Prader-Willi syndrome 312593 0
Condition category
Condition code
Human Genetics and Inherited Disorders 311100 311100 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Participants will be randomised to receive one of two exercises programs.
Intervention group participants will complete an exercise program, supervised 1:1 by an exercise professional.
Participants will exercise twice a week for 24 weeks (48 sessions in total). Each exercise session will last approximately 60 minutes.
All exercise sessions will take place in a community gym local to the participant.
The exercise program will be supervised by an exercise professional (usually a physiotherapist, exercise physiologist or personal trainer). Exercise professionals will be invited to participate based on their location and typical practice (e.g. working in paediatrics, neurological, or musculoskeletal areas). They will receive a training manual that includes details about the trial protocol, specialist advice on Prader-Willi syndrome, how to facilitate exercise in people with Prader-Willi syndrome, communication strategies, and behaviour management.
The exercise professional will complete an exercise log (either in hard copy or online) on behalf of the participant to document the exercises completed and any adverse events that occur.
Participants will also receive 2 planning sessions of 1-hour duration following the intervention period with a facilitator to encourage their ongoing participation in community exercise. These sessions will be conducted by an exercise professional either in person or via videoconference. The content of these sessions will be individualised and will aim to address barriers to taking part in ongoing community exercise. These sessions will take place approximately 1 month and 3 months after the end of the intervention.
Intervention code [1] 314313 0
Rehabilitation
Comparator / control treatment
Control group participants will also complete an exercise program, supervised 1:1 by an exercise professional.
Participants will exercise twice a week for 24 weeks (48 sessions in total). Each exercise session will last approximately 60 mins,
All exercise sessions will take place in a community gym local to the participant.
The exercise program will be supervised by an exercise professional (usually a physiotherapist, exercise physiologist or personal trainer).
Exercise professionals will be invited to participate based on their location and typical practice (e.g. working in paediatrics, neurological, or musculoskeletal areas). They will receive a training manual that includes details about the trial protocol, specialist advice on Prader-Willi syndrome, how to facilitate exercise in people with Prader-Willi syndrome, communication strategies, and behaviour management,
The exercise professional will complete an exercise log (either in hard copy of online) on behalf of the participant to document the exercises completed and any adverse events that occur.
Participants will also received 2 planning sessions of 1-hour duration following the intervention period with a facilitator to encourage their ongoing participation in community exercise. These sessions will be conducted by an exercise professional either in person or via videoconference. The content of these sessions will be individualised and will aim to address barriers to taking part in ongoing community exercise. These sessions will take place approximately 1 month and 3 months after the end of the intervention.
Control group
Active

Outcomes
Primary outcome [1] 319879 0
Muscle strength- of the arms and legs will be assessed using 1 repetition maximum (1RM) force generation tests. Composite measures of arm (chest press) and leg (leg press) strength will establish the amount of weight each participant can lift once.
Timepoint [1] 319879 0
Week 0 (baseline), week 25 (immediately post intervention) and week 52 (6-months post intervention)
Secondary outcome [1] 369762 0
Lean muscle mass will be assessed using a dual energy x-ray absorptiometry (DXA) whole body scan for total lean (muscle) mass and regional lean mass. DXA scans will be carried out on the same equipment at each time point for each participant at each site.
Timepoint [1] 369762 0
Week 0 (baseline), week 25 (immediately post intervention) and week 52 (6-months post intervention)
Secondary outcome [2] 369763 0
Sit-to-stand test: measures how long it takes to stand up and sit down 5 times
Timepoint [2] 369763 0
Week 0 (baseline), week 25 (immediately post intervention) and week 52 (6-months post intervention)
Secondary outcome [3] 369764 0
Weighted box-stacking test: measures how many boxes weighing 10kg can be stacked in one minute
Timepoint [3] 369764 0
Week 0 (baseline), week 25 (immediately post intervention) and week 52 (6-months post intervention)
Secondary outcome [4] 369765 0
Timed stair climb test: measures how long it takes to go up and down a standard flight of stairs
Timepoint [4] 369765 0
Week 0 (baseline), week 25 (immediately post intervention) and week 52 (6-months post intervention)
Secondary outcome [5] 369766 0
6-minute walk test: measures distance walked by the participant in 6 minutes
Timepoint [5] 369766 0
Week 0 (baseline), week 25 (immediately post intervention) and week 52 (6-months post intervention)
Secondary outcome [6] 369767 0
Physical activity levels (accelerometry): Actigraph GT3X+ accelerometers will be used to measure total physical activity, total sedentary time and the number of steps participants take during waking hours over 7 consecutive days.
Timepoint [6] 369767 0
Week 0 (baseline), week 25 (immediately post intervention) and week 52 (6-months post intervention)
Secondary outcome [7] 369768 0
Community participation (attendance): will be measured using the Adolescent Physical Activity Recall, the Adolescent Sedentary Activity, and the community section of the Participation and Environment Measure-Children and Youth questionnaires. These questionnaires measure what sports and other physical activities the participant does, how often and for how long and will be completed by participants and/or their family member or residential caregivers where necessary.
Timepoint [7] 369768 0
Week 0 (baseline), week 25 (immediately post intervention) and week 52 (6-months post intervention)
Secondary outcome [8] 369769 0
Community participation (involvement): will be measured using the community section of the Participation and Environment Measure-Children and Youth questionnaire. This questionnaire measures how involved participants feel in 10 activities and will be completed by participants and/or their family member or residential caregivers where necessary.
Timepoint [8] 369769 0
Week 0 (baseline), week 25 (immediately post intervention) and week 52 (6-months post intervention)
Secondary outcome [9] 369770 0
Health related quality of life: will be measured using the 9-item Child Health Utility (CHU-9D) instrument and the Quality of Life Inventory-Disability questionnaire. The CHU-9D will be completed by participants and/or their family members or residential caregivers where necessary. The Quality of Life Inventory-Disability questionnaire will be completed by family members or caregivers.
Timepoint [9] 369770 0
Week 0 (baseline), week 25 (immediately post intervention) and week 52 (6-months post intervention)
Secondary outcome [10] 369771 0
Healthcare utilisation: will be assessed via a health service utilisation questionnaire developed for the trial and completed by participants and/or their family members or residential caregivers where necessary. The questionnaire will collect data on hospital admissions and community allied health visits.
Timepoint [10] 369771 0
Week O (baseline, week 25 (immediately post intervention) and week 52 (6-months post intervention)
Secondary outcome [11] 369772 0
Adverse events: will be categorised as serious or non-serious, expected or unexpected, and related or unrelated to the trial will be documented in the participant’s exercise logbook completed by the health professional (usually a physiotherapist) supervising the intervention. Examples of possible adverse events are delayed onset muscle soreness, increased anxiety resulting in skin picking or a temper outburst (behavioural features of Prader-Willi syndrome) and food stealing.
Timepoint [11] 369772 0
During intervention phase of the trial (compiled at week 25, immediately post intervention)
Secondary outcome [12] 369773 0
Diet: will be documented by parents and carers (not participants) using the online version of the Australian Eating Survey
Timepoint [12] 369773 0
Week 0 (baseline), week 25 (immediately post intervention) and week 52 (6-months post intervention)
Secondary outcome [13] 369774 0
Gym experience: qualitative data about the participants’ experience of exercise will be collected from both groups (intervention and control). Data on acceptability, benefits and social interactions with gym users during training will be documented from semi-structured interviews with participants and their families. Photographs and video diaries will also be collected by participants using an iPod touch given to them on loan by the research team at trial commencement. Data on social interactions with other gym users will be documented in the participant’s exercise log during training by the health professional delivering the intervention. Data collection will be supplemented by observation (using ethnographic methods) for a subgroup of participants (n=10 participants), where 3 training sessions (one session during initial weeks, middle weeks and final weeks of training) will be observed.
Timepoint [13] 369774 0
During intervention phase of the trial (compiled at week 25, immediately post intervention)
Secondary outcome [14] 374140 0
Behaviour will be measured using the Developmental Behaviour Checklist questionnaire. The Developmental Behaviour Checklist -Parent version (DBC-P) will be completed by family members or residential caregivers of adolescents (aged 13-17 years) and the Developmental Behaviour Checklist -Adult version (DBC-A) will be completed by family members or residential caregivers of adults (aged 18 years and over).
Timepoint [14] 374140 0
Week 0 (baseline), week 25 (immediately post intervention) and week 52 (6-months post intervention)
Secondary outcome [15] 375930 0
Medicare Australia records will be retrieved with participant consent to determine medical services and pharmaceutical use over 12 months.
Timepoint [15] 375930 0
Week 52 (6-months post-intervention)

Eligibility
Key inclusion criteria
Each participant must meet all of the following criteria to be enrolled in this trial:
• Have genetically confirmed Prader-Willi syndrome,
• Aged between 13 and 60 years (inclusive) at the time of randomisation,
• Able to follow simple verbal instructions in English,
• Medical clearance from their general practitioners or physician certifying they can participate (where considered necessary based on answers to the pre-exercise screening questionnaire PAR-Q+),
• Provide a signed and dated informed consent form or has a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant’s behalf.
Minimum age
13 Years
Maximum age
60 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
People meeting any of the following criteria will be excluded from the trial:
• Has participated in progressive resistance training in the 3 months prior to randomisation
• Has a concurrent physical (e.g. severe arthritis), psychological (e.g. severe psychosis) or behavioural issue (e.g. violent behaviour) that might affect their ability to participate in a 24-week exercise program.
• Inability or unwillingness of participant or legally acceptable representative to give written informed consent.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Date of first participant enrolment
Anticipated
3/04/2020
Actual
24/02/2021
Date of last participant enrolment
Anticipated
Actual
16/09/2022
Date of last data collection
Anticipated
15/09/2023
Actual
Sample size
Target
60
Accrual to date
Final
58
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 14149 0
The Royal Childrens Hospital - Parkville
Recruitment hospital [2] 14150 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [3] 14151 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [4] 14152 0
Queensland Children's Hospital - South Brisbane
Recruitment hospital [5] 14153 0
Austin Health - Austin Hospital - Heidelberg
Recruitment postcode(s) [1] 27119 0
3052 - Parkville
Recruitment postcode(s) [2] 27120 0
2050 - Camperdown
Recruitment postcode(s) [3] 27121 0
4102 - Woolloongabba
Recruitment postcode(s) [4] 27122 0
4101 - South Brisbane
Recruitment postcode(s) [5] 27123 0
3084 - Heidelberg

Funding & Sponsors
Funding source category [1] 302612 0
Government body
Name [1] 302612 0
Medical Research Future Fund
Country [1] 302612 0
Australia
Primary sponsor type
University
Name
La Trobe University
Address
Kingsbury Drive,
Bundoora,
VIC 3086
Country
Australia
Secondary sponsor category [1] 302524 0
None
Name [1] 302524 0
Address [1] 302524 0
Country [1] 302524 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 303246 0
The Royal Children’s Hospital Melbourne Human Research Ethics Committee
Ethics committee address [1] 303246 0
Ethics committee country [1] 303246 0
Australia
Date submitted for ethics approval [1] 303246 0
Approval date [1] 303246 0
18/04/2019
Ethics approval number [1] 303246 0
2019.048

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 92994 0
Prof Nora Shields
Address 92994 0
Department of Physiotherapy, Podiatry, Prosthetics and Orthotics,
La Trobe University,
VIC 3086
Country 92994 0
Australia
Phone 92994 0
+61 3 9479 5852
Fax 92994 0
Email 92994 0
[email protected]
Contact person for public queries
Name 92995 0
Nora Shields
Address 92995 0
Department of Physiotherapy, Podiatry, Prosthetics and Orthotics,
La Trobe University,
VIC 3086
Country 92995 0
Australia
Phone 92995 0
+61 3 9479 5852
Fax 92995 0
Email 92995 0
[email protected]
Contact person for scientific queries
Name 92996 0
Nora Shields
Address 92996 0
Department of Physiotherapy, Podiatry, Prosthetics and Orthotics,
La Trobe University,
VIC 3086
Country 92996 0
Australia
Phone 92996 0
+61 3 9479 5852
Fax 92996 0
Email 92996 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
Individual participant data for published primary and secondary quantitative outcome measures.
When will data be available (start and end dates)?
Following the publication of the main trial outcomes (circa 2024), no end date.
Available to whom?
Data will be open access.
Available for what types of analyses?
Data will be available for any purpose including meta-analyses.
How or where can data be obtained?
Data will be deposited in the La Trobe University library repository.


What supporting documents are/will be available?

Doc. No.TypeCitationLinkEmailOther DetailsAttachment
2903Ethical approval    377484-(Uploaded-08-07-2019-12-31-15)-Study-related document.pdf
7455Study protocol    We aim to publish a study protocol in an open acce... [More Details]



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.